anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Restless legs syndrome (RLS) is a neurosensorimotor disorder of uncertain etiology that commonly disturbs sleep. The main feature of the disorder is paresthesia felt deep in the limbs that troubles the individual when he or she is at rest. The paresthesias of RLS commonly increase during the evening or the early part of the night. Patients are commonly less bothered by symptoms in the morning, unless they are severely affected. The repetitive movements that lead to arousal may also cause a subset of patients to become quite sleepy during the daytime. This sleepiness is usually not as severe as that found in patients with sleep apnea or narcolepsy but can be quite disruptive to quality of life and daytime functioning. Recent surveys indicate that RLS occurs in 10% to 15% of the North American population.

A common associated feature of RLS is Periodic Limb Movements during Sleep (PLMS). These are repetitive movements that typically occur as flexions of the foot, knee, and hip at intervals of 5 to 90 seconds. Most commonly, the interval is 20 to 40 seconds. The movements are present during non-rapid-eye-movement (REM) sleep and are less common during REM sleep. Population-based studies have found that RLS is associated with an increased risk for hypertension and coronary artery disease. Periodic leg movements -related repetitive nocturnal blood pressure fluctuations may contribute to this increased risk of cardiovascular disease especially in the elderly19. There is a possibility that dopamine agonist (DA) reduction of PLMS may mitigate the risk of the cardiovascular complications of RLS. The potential role of aplindore in reducing PLMS and nocturnal blood pressure fluctuations will be evaluated in this study.

Dopaminergic agents have become the most common medications used in the treatment of RLS and PLMS. Aplindore is an orally available, small molecule partial agonist of the D2 dopamine receptor. Preclinical in vitro and in vivo results have demonstrated the functional agonist selectivity of aplindore for supersensitive D2 receptors in the striatum, but not extra-striatal D2 receptors. Stimulation of D2 receptors in areas deficient in dopamine is attributed to aplindore's low intrinsic activity and high affinity for these receptors. Aplindore has been studied in preclinical toxicology studies in rats for up to 6 months and in monkeys for up to 1 year with safety margins in excess of 100-fold relative to projected human efficacious doses. The primary objective of this study is to assess the efficacy and tolerability of single doses of aplindore compared to placebo in RLS. The secondary objectives are to generate safety data with aplindore to support outpatient trials in RLS. b) To generate pilot data on the effects of aplindore on changes in blood pressure and heart rate associated with PLMS in patients with RLS. c) To understand the concentration-effect relationships of aplindore on RLS symptoms.
In the last two decades, alpha-synuclein (alpha-syn) assumed a prominent role as a major component and seeding structure of Lewy bodies (LBs). This concept is driving ongoing research on the pathophysiology of Parkinson's disease (PD). In line with this, alpha-syn is considered to be the guilty protein in the disease process, and it may be targeted through precision medicine to modify disease progression. Therefore, designing specific tools to block the aggregation and spreading of alpha-syn represents a major effort in the development of disease-modifying therapies in PD. The present article analyzes concrete evidence about the significance of alpha-syn within LBs. In this effort, some dogmas are challenged. This concerns the question of whether alpha-syn is more abundant compared with other proteins within LBs. Again, the occurrence of alpha-syn compared with non-protein constituents is scrutinized. Finally, the prominent role of alpha-syn in seeding LBs as the guilty structure causing PD is questioned. These revisited concepts may be helpful in the process of validating which proteins, organelles, and pathways are likely to be involved in the damage to meso-striatal dopamine neurons and other brain regions involved in PD.
BACKGROUND: The 8th AJCC TNM staging for non-metastatic lymph node-positive colon adenocarcinoma patients(NMLP-CA) stages solely by lymph node status, irrespective of the positivity of tumor deposits (TD). This study uses machine learning and Cox regression to predict the prognostic value of tumor deposits in NMLP-CA.
METHODS: Patient data from the SEER registry (2010-2019) was used to develop CSS nomograms based on prognostic factors identified via multivariate Cox regression. Model performance was evaluated by c-index, dynamic calibration, and Schmid score. Shapley additive explanations (SHAP) were used to explain the selected models.
RESULTS: The study included 16,548 NMLP-CA patients, randomized 7:3 into training (n = 11,584) and test (n = 4964) sets. Multivariate Cox analysis identified TD, age, marital status, primary site, grade, pT stage, and pN stage as prognostic for cancer-specific survival (CSS). In the test set, the gradient boosting machine (GBM) model achieved the best C-index (0.733) for CSS prediction, while the Cox model and GAMBoost model optimized dynamic calibration(6.473) and Schmid score (0.285), respectively. TD ranked among the top 3 most important features in the models, with increasing predictive significance over time.
CONCLUSIONS: Positive tumor deposit status confers worse prognosis in NMLP-CA patients. Tumor deposits may confer higher TNM staging. Furthermore, TD could play a more significant role in the staging system.
Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure. They will receive access to the HEALED website at the end of the 12-month intervention period.
Omax3\[TM\] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3\[TM\].
Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
Liver malignancies is a major cause of cancer-related mortality and the incidence is increasing. Patients with liver malignancies are often left with limited surgical treatment options due to extensive tumor burden or comorbidities. Ablation is a less invasive treatment for these patients that can be performed percutaneously, by laparoscopy or open surgery. Ablation during open surgery has a high potential of complications. Laparoscopic ablation presumably has a lower complication rate than during open surgery, yet still offers some of the same advantages needed for tumors in locations not favorable for percutaneous ablation. This study aims to compare laparoscopic ablation with ablation during open surgery to investigate a treatment option with a supposed lower complication rate and equally treatment effectiveness after one month.
The application discloses a pharmaceutical form of administration suitable for parenteral administration, which comprises the following: 1. One or more peptides prone to aggregation in dissolved or dispersed form, each peptide being in the form of its acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt 2. One of the above acids as free acid 3. Further additives and excipients (if appropriate) from the class consisting of the acids, surface-active substances, polymers, lipids or sugars. The processes for the production of a pharmaceutical form of administration are also disclosed in the specification along with the use of the pharmaceutical form of administration. The use described is the preparation of a medicament for parenteral administration in sex hormone-dependent benign and malignant diseases.
Opioid-induced constipation (OIC) is a common symptom in patients with cancer-related pain and requires burdensome self-titration of laxatives for prophylaxis and treatment. Consequently, naloxegol may have an important role in this setting. Naloxegol has been evaluated in relieving OIC with cancer patients in a randomized, double blind, placebo-controlled trial over 4 weeks with a 12-week extension phase. However, accrual was challenging and the trial was closed early. Given the complexity of cancer and its treatment, a key first step is to determine if evaluating naloxegol versus standard of care is feasible in the management of OIC in this setting.

Subjects will receive naloxegol 25mg daily or usual care for a 2-week initial treatment period followed by 3-day washout period, then a 2-week crossover treatment period where subjects will receive naloxegol or usual care. Treatment assignment during the initial and crossover treatment periods will be dictated by the randomization arm. Subjects will also have the option to participate in a 12-week extension phase of naloxegol.
The invention provides Clausena dentata (Willd.) Roem. cold treating tea and a production method thereof. Clausena dentata (Willd.) Roem., artemisia japonica, uncaria, garden balsam stems, leaf mustard, herb of Waterplantain Ottelia, water dropwort, lotus petiole, camellia japonica, folium ilicis cornutae and valeriana tangutica batal are used as raw materials. The method mainly includes the following steps of firstly, preparing materials according to the formula, and washing the materials; secondly, conducting drying and sterilizing; thirdly, selecting the dried raw materials according to the ratio; fourthly, grinding, mixing and frying the raw materials; fifthly, soaking the raw materials, conducting decoction multiple times, and extracting filtered fluid multiple times; sixthly, mixing filtered fluid, concentrating filtered fluid to obtain concentrated fluid, and drying concentrated fluid to obtain mixed powder; seventhly, conducting bagging and disinfecting to obtain the finished product. The Clausena dentata (Willd.) Roem. cold treating tea has the functions of treating colds, strengthening physique, enhancing immunity and preventing colds.
Introduction Intravesical treatment is currently dependent on catheterization which can cause urethral discomfort and risk of urinary tract infections in selected patient groups such as interstitial cystitis / bladder pain syndrome (IC/BPS), overactive bladder syndrome (OAB) and recurrent urinary tract infections (rUTI). This study describes real-life clinical experience of a minimally invasive syringe adapter (Ialudapter®) for catheter-free instillation of intravesical treatment.

Methods A retrospective study from a single center was performed. Quantitative and qualitative data was obtained on the use of the syringe adapter (IALUADAPTER®) in 61 patients with IC/BPS (n=48), rUTI (n=6) and mixed /other diagnoses (including OAB; n= 7) who were receiving intravesical therapy. The evaluation period was 6 months during 2018-2019. Reasons for trying the syringe adapter, reasons for continuing with it and occurrence of UTIs before and during the evaluation period were recorded. In addition, 3 year follow-up data were obtained to assess long-term usage of the syringe adapter.
Lichen Sclerosus (LS) is a cutaneous-mucosal dermatosis characterized by chronic changes in the trophism and maturation of the epithelium and the connective tissue. In females, the vulvar region is affected in about 90% of cases, often constituting the only site involved. In the adult female, the predominant symptoms are vulvar itching and burning due to scratching abrasions. Dyspareunia is an often associated. The clinical course is irregular but progressive and is characterized by periods of relative quiescence alternating with episodes of exacerbation of symptoms. The areas most affected are the labia minora, the periclitoral area, the navicular dimple, and the perianal area. The placement of LS in the context of immune-mediated dermatoses is the basis of the rationale for treatment with high potency topical corticosteroids. However, in some cases, local corticosteroid therapy is not sufficient to achieve adequate compensation of the pathology, and significant changes may set in of the vulvar anatomy resulting in a significant impact on the quality of life of the patient. This gives rise to the need to identify new treatments such a regenerative medicine. The term PRP (Platelet Rich Plasma) is used to describe a blood product blood generated by a two-step centrifugation process of whole blood of a patient to produce a concentration of platelets in a small volume of plasma. In addition to platelets, PRP contains large amounts of chemical mediators that promote angiogenesis, recruitment and proliferation of cells implicated in tissue regeneration and healing. PRP can be produced from autologous, homologous (donor) blood or from cord blood (CB-PRP). The main difference between PRP from peripheral blood (PB-PRP) and that from cord blood concerns the relative amount of growth factors and pro- and anti-inflammatory molecules. CB-PRP has been shown to be advantageous from a therapeutic point of view compared with PB-PRP because it contains higher concentrations of anti-inflammatory molecules. In addition, the use of CB-PRP allows for a final product that is not conditioned by the patient's age and by any associated comorbidities, which may instead compromise the quality of PB-PRP. Finally, the advantages of CB-PRP are related to lower production costs and to the greater ease of product preparation. The preparation process of CB-PRP involves a collection of cord blood following the expulsion of the placenta. The blood is then centrifugated using a two-step process. The final product is then injected on the vulvar surface under vulvoscopic guidance. Treatment with PRP is free of any major side effects. The objective of the following study is to evaluate the efficacy of CB-PRP versus placebo in the treatment of VLS.
Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
An amphibian emerging infectious disease (EID), chytridiomycosis, caused by Batrachochytrium dendrobatidis (Bd), originated in Asia but primarily led to declines and extinctions in amphibian populations outside of Asia. Host major histocompatibility complex (MHC) molecules exhibit high polymorphism, and the evolution of MHC can be influenced by recombination and pathogens. Previous studies have indicated that host MHC class II is associated with Bd resistance. In this study, I conducted recombination and selection tests on functional MHC IIß1 alleles from an Asian Bd-resistant anuran species (Bufo gargarizans) and an Australasian Bd-susceptible species (Litoria caerulea). Recombination at the same site was identified in both species, supporting the hypothesis that recombination contributes to MHC IIß1 diversity in amphibians. Positive selection was observed in MHC IIß1 alleles in both species. In L. caerulea, at least four amino acid sites were identified under significant positive selection in the MHC IIß1, whereas these sites were either negatively selected or conserved in B. gargarizans. This suggests these sites might be selected for Bd resistance. Hydrophobicity was detected in certain amino acid sites relating to Bd resistance, suggesting this physicochemical property may be a factor selected to counteract Bd infection. These findings of this study provide an evolutionary basis for understanding how amphibian MHC IIß1 may undergo selection in response to chytrid infection.
Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
A method for obtaining a strain of microorganisms modified to contain a fragment of a specific deoxyribonucleotide sequence, which method comprises: (I) purifying a fragment of a deoxyribonucleotide sequence by the following steps: (a) providing a population of cdna transcripts of the polyribonucleotides. (b) submit the cdna transcripts to the action of a restriction endonuclease preparation capable of catalyzing the hydrolysis of the cdna transcripts at each of the restriction sites. (c) fractionating the fragments produced by the action of the restriction endonuclease according to its length. (d) pretreating the dna to remove any 5''-phosphate terminal group. (e) incubating the dna with a restriction endonucelase capable of acting on the desired specific nucleotide sequence to produce two linear sub-fragments thereof. (f) fractionating the sub-fragments according to their length. (g) isolate the two sub-fragments, (h) assemble the sub-fragments covalently, in a reaction catalyzed by dna ligase, (I) fractionate the assembled dna molecules according to their length, (II) recombine the resulting product of the above sequence with a dna transfer vector and transfer it to a microorganism. (Machine-translation by Google Translate, not legally binding)
The invention discloses a traditional Chinese medicine pill for treating dementia and sudan, which is prepared from the following components in part by weight: the invention relates to a traditional Chinese medicine composition for treating diabetes, which is prepared from 18 traditional Chinese medicines of American ginseng, rhodiola rosea, prepared rhizome of rehmannia, orange and Chinese wolfberry, cornus officinalis, cistanche deserticola, polygala tenuifolia, calamus, salvia miltiorrhiza, eucommia ulmoides, dodder, achyranthes bidentata, poria with hostwood, Chinese yam, schisandra chinensis, fructus amomi, glossy privet fruit, eclipta alba and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has the functions of regulating the functions of brain, heart, liver, spleen and the like in two days, has the functions of regulating the functions of brain, heart, liver, spleen and the like, tonifying qi and replenishing essence, tonifying brain and generating marrow, promoting blood circulation to remove blood stasis, inducing resuscitation and refreshing brain, invigorating spleen and benefiting stomach, and strengthening body resistance to consolidate the constitution. 4. Can effectively improve the symptoms and physical signs of the dementia caused by deficiency of spleen and stomach, and strengthen the body resistance to consolidate the constitution.
PURPOSE:The titled remover, obtained by incorporating a water swellable gel material, e.g. sodium montmorillonite, with a specific organic solvent and readily handleable without causing danger of causing a fire and no smell of the organic solvent in the form of a gel or paste. CONSTITUTION:A nail beautifying enamel remover containing (A) a water swellable gel material, e.g. sodium montmorillonite, and (B) a hydrophilic organic solvent, readily soluble in nitrocellulose and having >=100 deg.C boiling point, e.g. lactone such as gamma-butyrolactone, acid amide such as tetramethylurea, ester such as methyl lactate or ethylene glycol monoacetate, or alcohol ether such as methyl cellosolve, in mixture. The amount of the component (A) to be incorporated in preferably 2-12%, particularly 5-7%. A fat or oil, e.g. squalane, is incorporated to protect the nail and a vitamin is incorporated to keep the health around the nail.
BACKGROUND: The use of biological grafts provides acceptable mid- and long-term results in native or prosthetic vascular infections. Several reports describe the successful use of bovine pericardium in case of vascular infections, mainly as a large patch to be sutured as a tubular graft. Recently, a novel prefabricated bovine pericardium graft (Biointegral Surgical No-React® Inc, Mississauga, ON, Canada) has been introduced in clinical practice with promising results. In this study, we report our preliminary experience utilizing Biointegral Surgical graft in case of native and or prosthetic aorto-iliac and infrainguinal infection.
METHODS: We retrospectively analyzed data from 20 patients with native or prosthetic aorto-iliac and infrainguinal infection who underwent in situ reconstruction (ISR) with a Biointegral Surgical No-React bovine pericardium prosthesis between October 2020 and February 2023 at the Vascular Surgery Unit of the Fondazione Policlinico Universitario Gemelli - IRCCS in Rome, Italy. All patients followed a standardized protocol including postoperative anticoagulation and long-term intravenous antibiotics.
RESULTS: The indication for surgery was: mycotic aortic aneurysm in 4 patients (20%), graft infection after abdominal aortic repair in 11 patients (55%), peripheral graft infection in 5 patients (25%). Complete excision of the infected aorta or prosthetic graft, surgical debridement and ISR were performed in all patients. Hospital mortality rate was 5% (n = 1) and graft-related mortality of 0%. During follow-up (median 13 months, range 6-34 months), reinfection was 5.2% and primary graft patency 94.7%.
CONCLUSIONS: The use of prefabricated bovine pericardial grafts represents a promising option for the treatment of native and prosthetic aorto-iliac and infrainguinal infections. The application of this biological graft with a standardized postoperative protocol has been associated with a satisfactory patency and reinfection rate without increased bleeding complications.
The present invention relates to a system for providing research results of interaction between AGER and SURM1 in body fluids, cells, and tissues derived from diabetic cardiovascular disease, cancer and dementia patients. A system includes: a web server which provides a webpage for a terminal of a main agent of research to connect thereto through a communications network; a scoring module which calculates a score so as to provide SURMylation probability for an AGE-R displayed as a score in each of SURMylation sites for the terminal of the main agent of research which connects to the webpage stored in the web server; and a database unit which stores data required for the scores in the SURMylation sites calculated by the scoring module, and the scores in the SURMylation sites calculated by the scoring module. Therefore, the system enables a user to receive the SURMylation probability of the AGE-R as the scores anytime and anywhere and to check results of a research on the AGE-R, thereby preventing a duplicate research on the AGE-R and improving research efficiency. In addition, interaction between the AGE-R and SURM1 proteins is first proposed. Further, the present invention helps draw correlation with a signal transmission path. Moreover, drugs, quasi-drugs, functional health food, daily supplies, etc., for treating all of diseases such as dementia, Alzheimer diseases, diabetic cardiovascular diseases, various cancers, various inflammation-related disorders, etc., can be easily developed by using or applying a part of the whole of the interaction between the AGE-R and the SURM1 proposed first in the present invention.